Clinical Trial Search

Phase 3 N=2,423 Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Primary: Mean Change From Baseline (BL) in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1, on Treatment Day 84 — 0.116; 0.082 Liter — p=0.001

GlaxoSmithKline Results Apr 2016 3.8% serious AE View details

Phase 3 N=399 Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Primary: Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period — 1.75; 1.34; 1.49; 1.26 Seizure Frequency per Week — p==0.261

UCB Pharma SA Results Apr 2016 3.5% serious AE View details

Phase 3 N=378 Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)

Atrial Fibrillation · Persistent Common Pulmonary Vein

Primary: Reconnection of Pulmonary Vein Electrogram After Adenosine Infusion — 92 participants

Yong Seog Oh Results Apr 2016 0.5% serious AE View details

Phase 3 N=105 Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Epilepsy

Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days) — 20; 19; 21; 20 Participants

UCB Pharma Results Apr 2016 0.0% serious AE View details

Phase 3 N=400 Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Primary: Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period — 2.15; 1.80; 1.96; 1.70 seizures per week — p==0.025

UCB Pharma Results Apr 2016 2.0% serious AE View details

Phase 3 N=56 Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

Unverricht-Lundborg Disease

Primary: Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4) — 17.45; -4.60; 12.34 Percent…

UCB Pharma Results Apr 2016 12.5% serious AE View details

Phase 3 N=20 Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study

Metabolic Syndrome X

Primary: Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions — 110531; 95140 #copies/100000 copies housekeeping gene

Laval University Results Apr 2016 0.0% serious AE View details

Phase 3 N=237 Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

Hepatitis C Virus

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12) — 99.1; 98.0 Percentage of participants — p=0.001

Merck Sharp & Dohme LLC Results Apr 2016 22.9% serious AE View details

Phase 3 N=310 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Hepatitis C Virus Infection

Primary: Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12) — 82.6; 96.8 Percentage of participants

Janssen Infectious Diseases BVBA Results Apr 2016 1.6% serious AE View details

Phase 3 N=421 Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)

Chronic Hepatitis C Virus

Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12) — 94.6 Percentage of participants — p=<0.001

Merck Sharp & Dohme LLC Results Apr 2016 4.2% serious AE View details

Phase 3 N=233 A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Anemia

Primary: Percentage of Participants Maintaining Their Mean Hemoglobin Concentration Within Plus or Minus 1 Gram/Deciliter of Their Reference Hemoglobin and Between the Target…

Hoffmann-La Roche Results Apr 2016 18.5% serious AE View details

Phase 3 N=2,424 Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

Influenza

Primary: Haemagglutination Inhibition (HI) Antibody Titers Against Each of the 4 Vaccine Influenza Strains — 716; 660; 740; 680 Subjects

GlaxoSmithKline Results Apr 2016 0.4% serious AE View details

Phase 3 N=476 Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Parkinson Disease · Idiopathic Parkinson Disease · Idiopathic Parkinson's Disease

Primary: Change From Baseline in Average "Off" Time (Hours Per Day) at Week 12 — -1.0; -1.1; -0.8 hours per day — p=0.4933

Merck Sharp & Dohme LLC Results Apr 2016 2.3% serious AE View details

Phase 3 N=611 Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)

Clostridium Difficile-Associated Diarrhea (CDAD)

Primary: Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 30 Days Post-treatment Follow-up. — 28.6; 30.8 Percentage of participants — p=0.2778

Optimer Pharmaceuticals LLC, a subsidiary of… Results Apr 2016 31.7% serious AE View details

Phase 3 N=28 A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease

Crohn's Disease

Primary: Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 8 — 75 percentage of…

AbbVie Results Apr 2016 28.6% serious AE View details